Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00
Provider: MarketLine (a Datamonitor Company)
$175.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Shionogi & Co Ltd Receives FDA Approval for Osphena (Ospemifene) for Treatment of Dyspareunia


Tuesday, 26 Feb 2013 09:00pm EST 

Shionogi & Co Ltd announced that the U.S. Food and Drug Administration (FDA) has approved Osphena (ospemifene) tablets for the treatment of moderate to severe dyspareunia (painful intercourse), a symptom of vulvar and vaginal atrophy (VVA), due to menopause. 

Company Quote

2380.0
50.0 +2.15%
1:50am EDT